AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

7 stories found

A clinician checks an AI evidence interface while weighing a treatment decision in a hospital.
Social good & healthUnited States+3 clusters01

Doctors are asking AI how to treat patients. Are we testing the right thing?

A doctor wondering which treatment to choose is a more consequential scene than an AI acing a diagnostic quiz. A new JAMA study analyzed 271 million questions submitted by 952,008 verified US clinicians to OpenEvidence between January 2024 and June 2026. Among physicians' queries, 33.1% concerned treatment and management, while 13.9% concerned diagnosis. More than half were categorized as clinical decision-making. Monthly active users rose from 355 to 703,265 over the study period, though that is growth on one platform, not a count of all US clinicians using AI. The authors say early-career physicians and nonprocedural specialties used it disproportionately. That should change the evaluation agenda. A tool can score well on diagnostic vignettes and still give weak medication guidance, omit a contraindication or misread an evolving guideline. The study did not examine the answers, clinical decisions or patient outcomes, and it could not tell whether a question was asked at the bedside or in preparation. Its topic labels came from a model, with a small clinician validation sample, and several authors disclosed employment at the platform. Those limits do not make the usage pattern unimportant; they make independent treatment-focused testing more urgent. The next studies should compare AI-assisted and usual-care decisions on real treatment tasks, measure errors as well as speed, and ask whether patients are better off. For now, the accurate headline is not that AI treats patients. It is that clinicians are increasingly asking it treatment questions before we have strong public evidence for those answers.

6 min
A patient reviews clear AI-prepared questions before meeting a surgeon, with an anxiety gauge and consultation timer both falling.
Social good & healthChina+4 clusters02

A local AI briefing cut pre-surgery anxiety and physician workload

A randomized phase II study offers a bounded example of medical AI that helped without pretending to replace the clinician. Researchers assigned 268 people newly diagnosed with prostate cancer and scheduled for radical prostatectomy to standard communication or an AI-assisted pathway. The intervention used a locally deployed large language model to prepare personalized answers to patient questions before the routine face-to-face discussion. Physicians remained responsible for the encounter and were blinded to group assignment. The AI-assisted group reported a mean post-communication GAD-7 anxiety score of 3.2, compared with 5.7 in the control group. Physician workload on the NASA-TLX scale averaged 39.9 versus 56.8, and routine communication time fell from 19.9 to 11.3 minutes. Satisfaction, emotions, and illness perceptions also improved. This is stronger evidence than a product testimonial, but it is not a general verdict on AI in medicine. The study was conducted at one cancer center, used a specific preoperative setting, measured near-term outcomes, and does not establish diagnostic accuracy, surgical outcomes, or long-term safety. The trial registry also still shows an earlier estimated enrollment of 160 and future completion dates, while the published paper reports 268 randomized participants; that record mismatch should be clarified. The design’s most important feature is the boundary: the model answered common questions in advance, responses were reviewed, and the surgeon still conducted the consent conversation. AI did not replace the relationship. It gave the relationship a better starting point.

10 min
A human hand holds a control line between concentrated AI infrastructure and an autonomous weapon beneath a UN-style assembly dome.
Law & informationGlobal+3 clusters03

The UN demands binding AI oversight and human control over lethal force

The UN secretary-general placed artificial intelligence alongside war, inequality, and climate change as one of four defining tests of power, arguing that control is moving from governments toward private corporations and from people toward machines. The speech called for binding international cooperation, independent oversight, and a multilateral framework for managing AI risk. It also drew a bright line around force: life-and-death decisions should not be surrendered to machines, and lethal autonomous weapons operating without meaningful human control should be outlawed. The diagnosis is institutional. Data, compute, and advanced models are concentrated in a small number of firms and states, while the people affected by automated decisions often have little access to the evidence or rules governing them. The speech points to the UN Global Dialogue on AI Governance and the Independent International Scientific Panel on AI as pieces of an emerging system. Neither currently functions as a world regulator with power to license models, compel records, or stop a deployment. A binding weapons instrument would also require states to agree on definitions, human-control standards, verification, and treatment of dual-use systems. The U.S. rejection of global AI control on the same day makes those limits impossible to ignore. The UN has articulated the global public interest. Its next test is whether states will grant enough authority, evidence access, and resources for independent oversight to become more than a forum for warnings.

9 min
A transparent AI industrial-policy ledger links ownership disclosures, federal contracts, data centers, and public oversight under a neutral evidence lens.
Law & informationUnited States+3 clusters04

Trump's AI push expands as family-linked ventures draw scrutiny

The Trump administration is accelerating artificial-intelligence infrastructure, defense technology, and federal adoption while technology ventures linked to members and allies of the president's family draw scrutiny. The Guardian's analysis says the policy and business tracks run in parallel and explicitly notes that it is not clear private financial interests are driving White House policy. An SEC filing independently confirms that Donald Trump Jr. and Eric Trump joined Dominari Holdings in creating American Data Centers. The reporting also describes 1789 Capital investments and federal business involving portfolio companies. Democratic lawmakers have asked the Defense Department's inspector general to examine whether awards were fairly granted; the companies and administration figures cited deny favoritism or say normal review processes were followed. Those facts establish relationships and oversight requests, not a proven quid pro quo. The stronger evidence-based angle is an expanding disclosure problem. AI industrial policy moves through loans, procurement, tax treatment, permitting, grid access, and private equity. Where political families or senior advisers have exposure to affected sectors, ownership, investment timing, recusals, award criteria, and agency review become material facts. Complete records can distinguish ordinary sector alignment from preferential treatment; without them, appearance fills the evidentiary gap.

9 min
Thousands of agent tokens flow through transparent monitoring pipes as a compute valve divides resources between capability and safety reservoirs.
Systemic riskUnited States+2 clusters05

Anthropic opens a dashboard on AI systems building their successors

Anthropic has proposed a public measurement framework for a frontier process that is usually hidden: how AI helps build AI, how agent actions are monitored, and how compute is allocated between capability and safety. Its snapshot says Claude leads 26% of measured R&D tasks and collaborates on more than 90%. On the company's most-used internal research platform, roughly 30,000 agents were operating at any one time in August 2026. Anthropic says every action on that platform passes through an online monitor, every action is ingested for offline review, about 0.002% of more than a billion decisions were blocked, and roughly fifty high-priority offline flags reach human review each week. In a sampled week, about 6% of AI-R&D compute went to safety work and about 12% of AI-driven AI-R&D compute did. The company acknowledges that compute is an imperfect proxy, the platform view is incomplete, its automation index depends on judgment, and cross-laboratory comparison lacks a common method. It plans external evaluator access. The publication matters because governance needs operational measures, not only capability scores and promises. But a dashboard can create false reassurance when coverage is confused with effectiveness or a low block rate is treated as a low risk rate. The next standard should combine process transparency with adversarial tests: how often monitors catch seeded failures, how quickly humans act, which actions cannot be reversed, how exceptions are granted, and whether outsiders can verify the entire chain.

8 min
A transparent lung scan and clinical evidence panel pass through several hospital environments while a performance signal changes between sites.
Social good & healthEurope+2 clusters06

Explainable AI improved oncologists’ lung-cancer predictions, but external validation exposed the limits

A multi-country study in Nature Medicine evaluated explainable AI support for treatment decisions in advanced non-small-cell lung cancer. The retrospective I3LUNG cohort included 2,396 patients treated with immunotherapy-based regimens across six centers in six countries. Models using routine clinical and blood data achieved test performance up to an area under the curve of 0.77 and outperformed traditional single biomarkers and clinical scores in the independent test set. In a separate usability study, twenty oncologists reviewed one hundred cases first without and then with model predictions and SHAP-based explanations. Sensitivity for predicting disease control increased from 0.72 to 0.87, with gains in accuracy and F1 performance; overall-survival prediction improved more modestly. The paper is valuable because it reports the limits alongside the gains. External-validation performance fell to an AUC range of 0.55 to 0.72, the complete multimodal sample was small, and added imaging, pathology, and genomic data did not produce a reliable benefit across test and external cohorts. Differences between patient populations may explain some decline, which is exactly why local calibration and prospective evaluation matter. The authors describe silent prospective validation in more than two thousand patients, another usability study, and a planned pragmatic randomized trial before deployment. The result is promising decision support, not autonomous clinical authority.

7 min
A wearable bioelectronic patch linking biosensing, an AI decision node, human oversight, and controlled therapy in a closed loop.
Social good & healthGlobal+2 clusters07

Gao et al., “AI-powered closed-loop wearable bioelectronics for personalized and autonomous healthcare”

A Nature Sensors review argues that AI-powered closed-loop wearables could move healthcare devices beyond passive data collection by connecting continuous biosensing directly to AI-guided decisions and therapeutic intervention. The authors emphasize that clinical value depends on the coordinated system—sensing, control, treatment, and human oversight—not any component alone. Long-term interface stability, robust control, transparent safety mechanisms, and evidence of patient benefit remain prerequisites for scalable use.

3 min